ArticleMolecular & cellular proteomics : MCP2012
Physical characterization of the "immunosignaturing effect".
Article in Molecular & cellular proteomics : MCP, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Immunosignature system for diagnosis of cancer.Proceedings of the National Academy of Sciences of the United States of America · 2014Trial
- Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine.Frontiers in immunology · 2022Article
- Technology of Informative Feature Selection for Immunosignature Analysis.Sovremennye tekhnologii v meditsine · 2021Article
- Rapid Response to Pandemic Threats: Immunogenic Epitope Detection of Pandemic Pathogens for Diagnostics and Vaccine Development Using Peptide Microarrays.Journal of proteome research · 2020Review
- Production of high-complexity frameshift neoantigen peptide microarrays.RSC advances · 2020Article
- Gain-Scanning for Protein Microarray Assays.Journal of proteome research · 2020Article
- Article
- Antibody characterization using immunosignatures.PloS one · 2020Article
- RNA Transcription and Splicing Errors as a Source of Cancer Frameshift Neoantigens for Vaccines.Scientific reports · 2019Article
- Diagnostic Profiling of the Human Public IgM Repertoire With Scalable Mimotope Libraries.Frontiers in immunology · 2019Article
- Using Frameshift Peptide Arrays for Cancer Neo-Antigens Screening.Scientific reports · 2018Article
- Entropy is a Simple Measure of the Antibody Profile and is an Indicator of Health Status: A Proof of Concept.Scientific reports · 2017Article
- Zika Virus Specific Diagnostic Epitope Discovery.Journal of visualized experiments : JoVE · 2017Article
- Protein Array-based Approaches for Biomarker Discovery in Cancer.Genomics, proteomics & bioinformatics · 2017Review
- Antibody repertoire profiling with mimotope arrays.Human vaccines & immunotherapeutics · 2017Article
- Immunological Tolerance, Pregnancy, and Preeclampsia: The Roles of Semen Microbes and the Father.Frontiers in medicine · 2017Article
- General Assessment of Humoral Activity in Healthy Humans.Molecular & cellular proteomics : MCP · 2016Article
- Time-Frequency Analysis of Peptide Microarray Data: Application to Brain Cancer Immunosignatures.Cancer informatics · 2015Article
- Epitope identification from fixed-complexity random-sequence peptide microarrays.Molecular & cellular proteomics : MCP · 2015Article
- Particle-Based Microarrays of Oligonucleotides and Oligopeptides.Microarrays (Basel, Switzerland) · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identifying new, effective biomarkers for diseases is proving to be a challenging problem. We have proposed that antibodies may offer a solution to this problem. The physical features and abundance of antibodies make them ideal biomarkers. Additionally, antibodies are often elicited early in the ontogeny of different chronic and infectious diseases. We previously reported that antibodies from patients with infectious disease and separately those with Alzheimer's disease display a characteristic and reproducible "immunosignature" on a microarray of 10,000 random sequence peptides. Here we investigate the physical and chemical parameters underlying how immunosignaturing works. We first show that a variety of monoclonal and polyclonal antibodies raised against different classes of antigens produce distinct profiles on this microarray and the relative affinities are determined. A proposal for how antibodies bind the random sequences is tested. Sera from vaccinated mice and people suffering from a fugal infection are individually assayed to determine the complexity of signals that can be distinguished. Based on these results, we propose that this simple, general and inexpensive system could be optimized to generate a new class of antibody biomarkers for a wide variety of diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.